CONCLUSION
ATHEROSCLEROSIS
Among stable adult patients with atherosclerosis, random allocation to interleukin‐1b inhibition with canakinumab as compared to placebo did not lower risk of incident frailty over 5 years. More randomized data are needed to understand the role of targeted anti‐inflammatory medications for prevention of frailty and functional decline in older adults.